From: Inequalities in pharmacologic treatment of spasticity in Sweden – health economic consequences of closing the treatment gap
Condition
Prevalence/100,000
Prevalence disabling spasticity
Stroke
715 [12]
17% [13,14,15]
CP
215 [16]
23% [17]
MS
190 [18]
33% [19]
TBI
150 [20]
19% [21]
SCI
32 [22, 23]
31% [24, 25]
